Skip to content
Isavuconazole
Cresemba (isavuconazole) is a small molecule pharmaceutical. Isavuconazole was first approved as Cresemba on 2015-10-15. It is used to treat aspergillosis and mucormycosis in the USA. It has been approved in Europe to treat aspergillosis.
Download report
Favorite
Searched
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name
Status
Last Update
cresembaNew Drug Application2019-12-02
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
aspergillosisEFO_0007157D001228B44
mucormycosisEFO_0007380D009091B46.5
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
J: Antiinfectives for systemic use
— J02: Antimycotics for systemic use
— J02A: Antimycotics for systemic use
— J02AC: Triazole and tetrazole derivatives
— J02AC05: Isavuconazole
HCPCS
No data
Clinical
Clinical Trials
44 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Invasive hydatidiform moleD002820D39.2———1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Invasive fungal infectionsD000072742——2—13
AspergillosisD001228EFO_0007157B44——3——3
Myeloid leukemia acuteD015470C92.0—21——2
CandidemiaD058387EFO_1001282——1——1
Invasive candidiasisD058365EFO_1001283B37——1——1
MycosesD009181B35-B49——1——1
Sars-cov-2D000086402——1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Invasive pulmonary aspergillosisD055744B44.0—2——13
MucormycosisD009091EFO_0007380B46.5—1——12
Hematologic neoplasmsD01933711———2
Myeloproliferative disordersD009196D47.1—1———1
Myelodysplastic syndromesD009190D46—1———1
NeutropeniaD009503D70—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients—25————25
PharmacokineticsD0105993————3
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameISAVUCONAZOLE
INNisavuconazole
Description
Isavuconazole is a 1,3-thiazole that is butan-2-ol which is substituted at positions 1, 2, and 3 by 1,2,4-triazol-1-yl, 2,5-difluorophenyl, and 4-(p-cyanophenyl)-1,3-thiazol-2-yl groups, respectively. It is an antifungal drug used for the treatment of invasive aspergillosis and invasive mucormycosis. It has a role as an ergosterol biosynthesis inhibitor, an EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor and an orphan drug. It is a member of 1,3-thiazoles, a nitrile, a difluorobenzene, a tertiary alcohol, a triazole antifungal drug and a conazole antifungal drug.
Classification
Small molecule
Drug classsystemic antifungals (miconazole type)
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
C[C@@H](c1nc(-c2ccc(C#N)cc2)cs1)[C@](O)(Cn1cncn1)c1cc(F)ccc1F
Identifiers
PDB—
CAS-ID241479-67-4
RxCUI1720882
ChEMBL IDCHEMBL409153
ChEBI ID85979
PubChem CID6918485
DrugBankDB11633
UNII ID60UTO373KE (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 2,964 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
15,787 adverse events reported
View more details